Ken Griffin Cellectis S.A. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cellectis S.A. stock. As of the latest transaction made, Citadel Advisors LLC holds 3,100 shares of CLLS stock, worth $4,867. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,100
Previous 5,900
47.46%
Holding current value
$4,867
Previous $12,000
58.33%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding CLLS
# of Institutions
33Shares Held
13.5MCall Options Held
5.9KPut Options Held
1.4K-
Long Focus Capital Management, LLC San Juan, PR4.62MShares$7.25 Million0.28% of portfolio
-
B Group, Inc. Dallas, TX3.08MShares$4.84 Million3.39% of portfolio
-
Capital International Investors Los Angeles, CA1.85MShares$2.9 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL1.44MShares$2.26 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$2.26 Million0.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $71.5M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...